REG - e-Therapeutics plc - Total Voting Rights

E-TherapeuticsAnnouncement

31/01/2023 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230131:nRSe2970Oa&default-theme=true

RNS Number : 2970O  e-Therapeutics plc  31 January 2023

E-THERAPEUTICS PLC

 

("e-therapeutics" or the "Company")

 

Total Voting Rights

 

London, UK, 31 January 2023 - e-therapeutics plc (AIM: ETX), the drug
discovery company, announces that in accordance with the Financial Conduct
Authority's Disclosure and Transparency Rules, the Company has 582,159,332
ordinary shares of 0.1 pence each in issue, none of which are held in
treasury. Therefore, the total number of voting rights in the Company is
582,159,332.

 

The above figure of 582,159,332 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company.

 

For further information, please contact:

 

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)1993 883 125
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary Computational Biology Platform enables the generation and
analysis of biological network models, providing a novel and mechanistic
approach to drug discovery that explicitly considers the true complexity of
biology and makes more reliable predictions from large complex data sets and
ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive
and integrated hepatocyte-centric data and information resource.  The Company
generates, prioritises and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.

 

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes
in the liver and the specific silencing of novel disease-associated genes,
identified by ETX's Computational Biology Platform.  The focus on hepatocytes
offers the opportunity to work across a wide variety of diseases.  The liver
is a highly metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of action.

 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates
in several therapeutic areas including haematology, cardiovascular disease
and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered with
biopharma companies such as Novo Nordisk, Galapagos NV and iTeos
Therapeutics using its computational network biology approach across a
diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRZZGFMDGFGFZM